HeimN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Við síðustu lokun
34,07 R$
Árabil
25,64 R$ - 44,18 R$
Markaðsvirði
12,91 ma. USD
Meðalmagn
182,00
V/H-hlutf.
-
A/V-hlutfall
-
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 805,50 m. | 28,33% |
Rekstrarkostnaður | 302,50 m. | 5,11% |
Nettótekjur | 153,70 m. | 49,08% |
Hagnaðarhlutfall | 19,08 | 16,13% |
Hagnaður á hvern hlut | 1,88 | 11,24% |
EBITDA | 234,70 m. | 54,31% |
Virkt skatthlutfall | 35,80% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,48 ma. | 37,57% |
Heildareignir | 4,63 ma. | 24,55% |
Heildarskuldir | 1,38 ma. | 22,09% |
Eigið fé alls | 3,25 ma. | — |
Útistandandi hlutabréf | 100,36 m. | — |
Eiginfjárgengi | 1,05 | — |
Arðsemi eigna | 12,77% | — |
Ávöxtun eigin fjár | 15,76% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 153,70 m. | 49,08% |
Handbært fé frá rekstri | 388,40 m. | 60,16% |
Reiðufé frá fjárfestingum | -52,90 m. | 22,55% |
Reiðufé frá fjármögnun | 37,30 m. | 112,86% |
Breyting á handbæru fé | 372,80 m. | 421,10% |
Frjálst peningaflæði | 312,50 m. | 15,90% |
Um
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Framkvæmdastjóri
Stofnsett
1992
Höfuðstöðvar
Vefsvæði
Starfsfólk
2.000
